Company intelligence / Profile preview
Kinaset Therapeutics
Medfield, Massachusetts, United Stateskinasettherapeutics.com ↗
- Ownership
- Private
- Employees
- ~5
- Development stage
- Other
01
Overview
Kinaset's lead candidate frevecitinib (KN-002), a novel inhaled pan-JAK inhibitor, has completed Phase 1 clinical trials showing clinically relevant reductions in fractional exhaled nitric oxide (FeNO) in patients with mild and moderate-to-severe asthma. The FDA has cleared its IND application, and the company plans to begin a Phase 2b dose ranging trial in mid-2025[8].
- Therapeutic areas
- Pulmonology
- Modalities
- Small molecule drugsinhaled therapeutics
- Industry
- Biotech
02
Drug pipeline
1 assetBeyond the preview
Go deeper on Kinaset Therapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Kinaset Therapeutics.